BIVV020 in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Status:
Not yet recruiting
Trial end date:
2025-04-09
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR
- Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR
Secondary Objectives:
- To assess the overall efficacy of BIVV020 in prevention or treatment of AMR
- To characterize the safety and tolerability of BIVV020 in kidney transplant participants
- To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant
participants
- To evaluate the immunogenicity of BIVV020